TriSalus Life Sciences to Present New Data at SIR 2026 Annual Scientific Meeting
TriSalus Life Sciences, Inc., a clinical-stage oncology company focused on improving outcomes for patients with solid tumors, has announced its participation in the prestigious Society of Interventional Radiology Annual Scientific Meeting 2026. The event will take place from April 11 to April 15, 2026, in Toronto, bringing together leading physicians, researchers, and innovators in the field of interventional radiology.
At this global platform, TriSalus will present new clinical and preclinical data highlighting the effectiveness of its proprietary Pressure Enabled Drug Delivery™ (PEDD™) technology. The company aims to demonstrate how this innovative platform can significantly enhance therapeutic delivery across multiple disease states, particularly in oncology and embolization procedures.
Advancing Oncology Through Innovative Drug Delivery
TriSalus Life Sciences is dedicated to transforming cancer care by combining advanced drug delivery technologies with established treatment protocols. The company’s PEDD™ platform is designed to optimize the delivery of therapeutics directly to targeted tissues, improving drug penetration and potentially enhancing treatment efficacy.
Traditional delivery methods often face limitations such as inadequate drug distribution and reduced penetration into tumors. PEDD™ addresses these challenges by using controlled pressure to deliver therapeutic agents more effectively into diseased tissues. This approach has the potential to improve outcomes for patients with difficult-to-treat solid tumors, including liver cancers and metastatic disease.
The data being presented at SIR 2026 further reinforces the versatility of PEDD™, showcasing its application across multiple clinical scenarios—from liver-directed therapies to gynecological interventions.
Key Presentations at SIR 2026
TriSalus will feature several important presentations during the conference, each highlighting different aspects of the PEDD™ platform and its clinical relevance.
1. Enhancing Tumor Penetration in Preclinical Models
Date: April 13, 2026
Time: 12:10 PM ET
Presenter: David Jaroch
This poster presentation focuses on preclinical research using an Oncopig model to evaluate the effectiveness of PEDD™ during embolization procedures. The study, titled “Pressure Enabled Drug Delivery During Delivery of Embolic Spheres Enhances Hepatic Tumor Penetration,” demonstrates how PEDD™ improves the distribution and penetration of embolic agents within liver tumors.
The findings suggest that PEDD™ may significantly enhance the ability of therapeutic agents to reach deeper tumor regions, which is critical for improving treatment outcomes in hepatic malignancies. These results provide a strong foundation for further clinical investigation.
2. Clinical Experience in Neuroendocrine Tumor Metastases
Date: April 13, 2026
Time: 3:18 PM ET
Presenters: Adam Robinson and Richard Marshall
This scientific session presentation explores the use of PEDD™ in patients with neuroendocrine tumor metastases to the liver. Conducted as a single-center study, the research compares outcomes before and after the introduction of PEDD™ technology.
The study highlights improvements in embolization procedures, suggesting that PEDD™ may enhance therapeutic delivery and clinical effectiveness. By enabling better distribution of embolic materials, the platform could contribute to improved tumor control and patient outcomes.
This presentation is particularly significant as it bridges the gap between preclinical findings and real-world clinical application, demonstrating the translational potential of PEDD™.
3. Novel Approaches to Uterine Artery Embolization
Date: April 14, 2026
Time: 3:36 PM ET
Presenter: Francis Kang
This session examines the application of PEDD™ in uterine artery embolization (UAE), a minimally invasive procedure used to treat conditions such as uterine fibroids.
Titled “Novel Approaches to Uterine Artery Embolization: A Clinical Assessment of Safety and Efficacy Using a Pressure Enabled Drug Delivery Device,” the study evaluates both safety and effectiveness in a clinical setting.
The findings suggest that PEDD™ can enhance procedural outcomes by improving the precision and distribution of embolic agents. This expands the potential use of the technology beyond oncology into broader interventional radiology applications.
Expanding the Evidence Base for PEDD™
In addition to the highlighted presentations, TriSalus has made further abstracts and supporting materials available through its official publications portal. These resources provide deeper insights into ongoing research and the evolving clinical evidence supporting PEDD™.
The growing body of data underscores the platform’s adaptability across different therapeutic areas. From preclinical models to human studies, the evidence consistently points to improved drug delivery and enhanced treatment performance.
Leadership Perspectives
Mary Szela, Chief Executive Officer of TriSalus Life Sciences, emphasized the significance of these presentations in advancing the company’s mission:
These presentations continue to expand the growing body of evidence supporting PEDD as a differentiated approach to improving therapeutic delivery.”
She also highlighted the broad applicability of the platform, noting its success across multiple treatment areas, including liver-directed therapies and uterine artery embolization.
Richard Marshall echoed this sentiment, emphasizing the company’s commitment to innovation in interventional oncology:
Our work reflects a broader commitment to advancing interventional oncology and embolization techniques.”
He further expressed enthusiasm about the diversity of data being presented, ranging from preclinical research to investigator-initiated clinical studies, and its implications for improving patient outcomes.
The Importance of SIR 2026
The Society of Interventional Radiology Annual Scientific Meeting is one of the most influential gatherings in the field of interventional radiology. It serves as a platform for showcasing cutting-edge research, sharing clinical experiences, and fostering collaboration among healthcare professionals worldwide.
Participation in this event underscores TriSalus Life Sciences’ position as a leader in innovative drug delivery solutions. By presenting at SIR 2026, the company gains visibility among key stakeholders, including physicians, researchers, and industry experts.
Future Implications for Patient Care
The advancements highlighted at SIR 2026 have significant implications for the future of patient care. Improved drug delivery mechanisms like PEDD™ could lead to:
- More effective tumor targeting
- Enhanced therapeutic outcomes
- Reduced systemic side effects
- Expanded treatment options for complex conditions
As the healthcare industry continues to move toward precision medicine, technologies that enable targeted and efficient treatment delivery will play a crucial role.
TriSalus Life Sciences’ participation in the SIR 2026 Annual Scientific Meeting marks an important milestone in its journey to transform cancer treatment and interventional radiology practices. Through its innovative PEDD™ platform, the company is addressing critical challenges in drug delivery and opening new possibilities for patient care.
The data presented at the conference not only strengthens the scientific foundation of PEDD™ but also highlights its versatility across multiple clinical applications. As research continues to evolve, TriSalus is well-positioned to make a lasting impact on the future of oncology and minimally invasive therapies.
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s three FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD) approach to deliver a range of therapeutics: the TriNav® Infusion System and TriNav Infusion System LV for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.
